TT Capital Management LLC bought a new position ... TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome ...
Financially, HURA's cash burn rate suggests a need for additional funding, despite recent financing that extends cash runway into late 2025. Overall, HURA's high-risk profile and early-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback